Question (apologies if the answer is obvious):
Could someone explain the supply chain for MPL i.e. what company actually manufactures and supplies the base compound - is it Elanco given they own the MPL IP for canine cancer and what company(its) formulate the base compound into the required dosage/pill format? Do they use or are they able to use Epichem to do this.
I ask this question to ensure PAA are able to control the supply, delivery and formulation of MPL in large quantities when required. I would hate to think the supply of the base compound could be withheld or PAA could be held hostage from the supply side regardless of the IP owned by PAA
Charting PAA, page-549
-
- There are more pages in this discussion • 351 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $43.18K | 243.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70085 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 256095 | 5 |
View Market Depth
| Last trade - 12.41pm 13/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |